Innovative technologies are revolutionizing cancer research, driving advancements in diagnosis, treatment, and drug development. Artificial intelligence (AI) and machine learning are transforming early detection by analyzing complex imaging data and predicting treatment outcomes with greater accuracy.
Next-generation sequencing (NGS) is unlocking insights into genetic mutations, enabling personalized therapies tailored to individual cancer profiles. CRISPR-Cas9 gene editing offers groundbreaking potential by targeting and correcting genetic errors linked to cancer development.
Meanwhile, 3D bioprinting and organ-on-a-chip technologies are creating precise tumor models, accelerating drug testing while reducing reliance on traditional methods. Advances in immunotherapy, powered by deep molecular insights, are enhancing the immune system’s ability to fight cancer. These innovations are reshaping cancer research, offering hope for better treatments and improved patient outcomes.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China